Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer

Autor: M.A.P. Van Ruler, D.A.R.H. Grootenboers, A J E Vulink, Marije Slingerland, Corrie A.M. Marijnen, Femke P. Peters, K J Neelis, Marta Fiocco
Rok vydání: 2017
Předmět:
Male
medicine.medical_specialty
Esophageal Neoplasms
medicine.medical_treatment
Antineoplastic Agents
Adenocarcinoma
Disease-Free Survival
chemoradiotherapy
paclitaxel
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
medicine
Humans
esophageal cancer
030212 general & internal medicine
External beam radiotherapy
Esophagus
Aged
Retrospective Studies
Aged
80 and over
business.industry
Gastroenterology
Retrospective cohort study
General Medicine
Middle Aged
Esophageal cancer
medicine.disease
Dysphagia
Carboplatin
Surgery
Treatment Outcome
medicine.anatomical_structure
chemistry
030220 oncology & carcinogenesis
carboplatin
Carcinoma
Squamous Cell
adverse effects
Female
Esophageal Squamous Cell Carcinoma
medicine.symptom
business
Chemoradiotherapy
Follow-Up Studies
Zdroj: Diseases of the Esophagus, 30(4)
ISSN: 1442-2050
1120-8694
DOI: 10.1093/dote/dow033
Popis: Patients with nonmetastatic esophageal cancer not suitable for surgery can be treated with definitive chemoradiotherapy with curative intent. The purpose of this retrospective study is to evaluate the clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel. Medical records were reviewed of patients treated for nonmetastatic squamous cell or adenocarcinoma of the esophagus between January 2009 and December 2013 in two collaborating institutes. Treatment consisted of external beam radiotherapy (28 fractions of 1.8 Gy) and 6 weekly courses of carboplatin (AUC = 2) and paclitaxel (50 mg/m2). Data on survival, progression, toxicity, and effect on dysphagia were recorded. Sixty-six patients were included. Median overall survival (OS) was 13.1 months (95% CI 4.7-21.5 months) and a 2-year OS was 30% (95% CI 18%-42%). At 2 years, 26% of patients developed local progression (95% CI 15%-37%) and 49% developed distant metastases (95% CI 36%-64%). Acute toxicity grade ≥3 was observed in 47% of patients. Late adverse events grade ≥3 were seen in 20%, mostly esophageal stenoses. Of patients with available data 3 months after treatment, 70% had relief of dysphagia. Definitive chemoradiotherapy led to a median OS of 13 months. Toxicity was common, mostly due to hematological toxicity. Given the relatively short median survival, an adequate selection of patients for this intensive treatment is required.
Databáze: OpenAIRE
Externí odkaz: